Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours

Head-to-head comparisons of the efficacy of treatments for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have not yet been reported. This study used a series of matching-adjusted indirect comparisons to indirectly compare the effectiveness of [177Lu]Lu-DOTA-TATE to everolimus, sunitinib a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mohid S. Khan, Elaine Stamp, Cormac Sammon, Tessa Brabander, Wouter W. de Herder, Marianne E. Pavel
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Overall survival Progression-free survival Comparative effectiveness Best supportive care Medicine R Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d4894036001b4790bd19ca639cc337bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d4894036001b4790bd19ca639cc337bc
record_format	dspace
spelling	oai:doaj.org-article:d4894036001b4790bd19ca639cc337bc2021-11-12T04:27:44ZMatching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours1359-634910.1016/j.ejcsup.2021.06.002https://doaj.org/article/d4894036001b4790bd19ca639cc337bc2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1359634921000021https://doaj.org/toc/1359-6349Head-to-head comparisons of the efficacy of treatments for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have not yet been reported. This study used a series of matching-adjusted indirect comparisons to indirectly compare the effectiveness of [177Lu]Lu-DOTA-TATE to everolimus, sunitinib and best supportive care (BSC) for extending progression-free survival and overall survival in patients with advanced, unresectable gastrointestinal (GI)-NETs and P-NETs. The results of the main analysis suggest that after accounting for differences in key prognostic variables, the hazard of progression was 62% (hazard ratio [HR], 0.38; confidence interval [CI]95 0.25–0.58) and 65% (HR 0.35 CI95 0.21–0.59) lower in patients with GI-NETs treated with [177Lu]Lu-DOTA-TATE than in those treated with everolimus and BSC, respectively. Similarly, the hazard of progression was 64% (HR 0.36 CI95 0.18–0.70), 54% (HR 0.46 CI95 0.30–0.71) and 79–87% (HR 0.21 CI95 0.13–0.32; HR 0.13 CI95 0.08–0.22) lower in patients with P-NET treated with [177Lu]Lu-DOTA-TATE than in those treated with sunitinib, everolimus and BSC, respectively. The hazard of death was 58% (HR 0.42 CI95 0.25–0.72), 47% (HR 0.53 CI95 0.33–0.87) and 44–64% (HR 0.56 CI95 0.36–0.90; HR 0.34 CI95 0.20–0.57) lower in P-patients with NET treated with [177Lu]Lu-DOTA-TATE than in those treated with sunitinib, everolimus and BSC, respectively. While our results must be interpreted with caution given the non-randomised nature of the comparisons and the potential for residual confounding, the magnitude of the effect sizes we observe and their consistency across comparators suggest that [177Lu]Lu-DOTA-TATE may be a more effective treatment option than everolimus, sunitinib and BSC in advanced, unresectable GEP-NETs.Mohid S. KhanElaine StampCormac SammonTessa BrabanderWouter W. de HerderMarianne E. PavelElsevierarticleOverall survivalProgression-free survivalComparative effectivenessBest supportive careMedicineRNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENEJC Supplements, Vol 16, Iss , Pp 5-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Overall survival Progression-free survival Comparative effectiveness Best supportive care Medicine R Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Overall survival Progression-free survival Comparative effectiveness Best supportive care Medicine R Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Mohid S. Khan Elaine Stamp Cormac Sammon Tessa Brabander Wouter W. de Herder Marianne E. Pavel Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
description	Head-to-head comparisons of the efficacy of treatments for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have not yet been reported. This study used a series of matching-adjusted indirect comparisons to indirectly compare the effectiveness of [177Lu]Lu-DOTA-TATE to everolimus, sunitinib and best supportive care (BSC) for extending progression-free survival and overall survival in patients with advanced, unresectable gastrointestinal (GI)-NETs and P-NETs. The results of the main analysis suggest that after accounting for differences in key prognostic variables, the hazard of progression was 62% (hazard ratio [HR], 0.38; confidence interval [CI]95 0.25–0.58) and 65% (HR 0.35 CI95 0.21–0.59) lower in patients with GI-NETs treated with [177Lu]Lu-DOTA-TATE than in those treated with everolimus and BSC, respectively. Similarly, the hazard of progression was 64% (HR 0.36 CI95 0.18–0.70), 54% (HR 0.46 CI95 0.30–0.71) and 79–87% (HR 0.21 CI95 0.13–0.32; HR 0.13 CI95 0.08–0.22) lower in patients with P-NET treated with [177Lu]Lu-DOTA-TATE than in those treated with sunitinib, everolimus and BSC, respectively. The hazard of death was 58% (HR 0.42 CI95 0.25–0.72), 47% (HR 0.53 CI95 0.33–0.87) and 44–64% (HR 0.56 CI95 0.36–0.90; HR 0.34 CI95 0.20–0.57) lower in P-patients with NET treated with [177Lu]Lu-DOTA-TATE than in those treated with sunitinib, everolimus and BSC, respectively. While our results must be interpreted with caution given the non-randomised nature of the comparisons and the potential for residual confounding, the magnitude of the effect sizes we observe and their consistency across comparators suggest that [177Lu]Lu-DOTA-TATE may be a more effective treatment option than everolimus, sunitinib and BSC in advanced, unresectable GEP-NETs.
format	article
author	Mohid S. Khan Elaine Stamp Cormac Sammon Tessa Brabander Wouter W. de Herder Marianne E. Pavel
author_facet	Mohid S. Khan Elaine Stamp Cormac Sammon Tessa Brabander Wouter W. de Herder Marianne E. Pavel
author_sort	Mohid S. Khan
title	Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
title_short	Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
title_full	Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
title_fullStr	Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
title_full_unstemmed	Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
title_sort	matching-adjusted indirect treatment comparison of [177lu]lu-dota-tate, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: relative effectiveness of [177lu]lu-dota-tate in gastroenteropancreatic neuroendocrine tumours
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/d4894036001b4790bd19ca639cc337bc
work_keys_str_mv	AT mohidskhan matchingadjustedindirecttreatmentcomparisonof177luludotatateeverolimusandsunitinibinadvancedunresectablegastroenteropancreaticneuroendocrinetumoursrelativeeffectivenessof177luludotatateingastroenteropancreaticneuroendocrinetumours AT elainestamp matchingadjustedindirecttreatmentcomparisonof177luludotatateeverolimusandsunitinibinadvancedunresectablegastroenteropancreaticneuroendocrinetumoursrelativeeffectivenessof177luludotatateingastroenteropancreaticneuroendocrinetumours AT cormacsammon matchingadjustedindirecttreatmentcomparisonof177luludotatateeverolimusandsunitinibinadvancedunresectablegastroenteropancreaticneuroendocrinetumoursrelativeeffectivenessof177luludotatateingastroenteropancreaticneuroendocrinetumours AT tessabrabander matchingadjustedindirecttreatmentcomparisonof177luludotatateeverolimusandsunitinibinadvancedunresectablegastroenteropancreaticneuroendocrinetumoursrelativeeffectivenessof177luludotatateingastroenteropancreaticneuroendocrinetumours AT wouterwdeherder matchingadjustedindirecttreatmentcomparisonof177luludotatateeverolimusandsunitinibinadvancedunresectablegastroenteropancreaticneuroendocrinetumoursrelativeeffectivenessof177luludotatateingastroenteropancreaticneuroendocrinetumours AT marianneepavel matchingadjustedindirecttreatmentcomparisonof177luludotatateeverolimusandsunitinibinadvancedunresectablegastroenteropancreaticneuroendocrinetumoursrelativeeffectivenessof177luludotatateingastroenteropancreaticneuroendocrinetumours
_version_	1718431319211376640

Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours

Ejemplares similares